MEDICINE DETAILS
Opdivo
Active ingredient: Nivolumab
Neutral reference profile for an independent medicine-access consultancy enquiry about Opdivo (Nivolumab). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Opdivo used for?
Opdivo (nivolumab) is indicated for the treatment of patients with:
- Metastatic melanoma as a single agent or in combination with ipilimumab
- Metastatic non-small cell lung cancer (NSCLC) whose cancer progressed on or after chemotherapy
- Advanced renal cell carcinoma who have received prior anti-angiogenic therapy
- Classical Hodgkin lymphoma that has relapsed or progressed after other treatments
- Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or within 6 months of receiving platinum-based chemotherapy
- Locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy
- Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
- Hepatocellular carcinoma in patients who have been previously treated with sorafenib
- For the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Opdivo identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
10 mg/ml · 1 vial (4 ml) Catalogue organisation: Bristol-Myers Squibb GmbH & Co. KGaA
-
10 mg/ml · 1 vial (10 ml) Catalogue organisation: Bristol-Myers Squibb GmbH & Co. KGaA
-
10 mg/ml · 1 vial (12 ml) Catalogue organisation: Bristol-Myers Squibb GmbH & Co. KGaA
-
600 mg solution for injection · 1 vial (5 ml) Catalogue organisation: Bristol-Myers Squibb GmbH & Co. KGaA
OFFICIAL SOURCES
Check the Opdivo record at an official source.
Search for “Opdivo” or “Nivolumab”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Opdivo.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Opdivo
01What is Opdivo?＋
This directory record associates the brand name Opdivo with the active ingredient Nivolumab. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Opdivo strengths and packs are recorded?＋
The catalogue currently shows: 10 mg/ml · 1 vial (4 ml); 10 mg/ml · 1 vial (10 ml); 10 mg/ml · 1 vial (12 ml); 600 mg solution for injection · 1 vial (5 ml). Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Opdivo?＋
Catalogue records currently name: Bristol-Myers Squibb GmbH & Co. KGaA. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Opdivo?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Opdivo, payment request, stock guarantee or binding offer.
06Can I buy Opdivo from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.